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Eva Feldman, MD, PhD, FAAN
We thank Drs Lang and Obeso for their perspectives on
our article.1 As described in our article and their letter, the mecha-
nisms underlying neurodegenerative diseases are complex and
therefore require multiple different treatment strategies. Because
Alzheimer’s disease, Huntington’s disease, amyotrophic lateral scle-
rosis, spinal muscular atrophy, and Parkinson’s disease (PD) are
therapeutically challenging disorders, there is increasing interest in
cellular therapies. Current research is centered on the ability of
stem and progenitor cells to provide direct replacement of dis-
eased or lost cells, enhance neuronal circuitry, and enrich the local
neuronal environment. Clearly, it is a combination of these factors
that contributes to the attractiveness of stem cells as a potential
therapy for complex neurodegenerative disorders, including PD.
We fully agree with Drs Lang and Obeso that PD is
characterized by a complex loss of cell types and pathways. Yet
while multiple cell types are affected in PD, classical approaches
to cellular therapies over the past 2 decades have focused on
replacement of lost dopaminergic neurons.2–5 This has yielded
promising results in vivo and modest functional improvements
in patients. In a review article, we contend that we should pro-
vide the state of current research, and improving dopaminergic
neuronal replacement remains the topic of numerous preclinical
and clinical studies for PD.2–5 Given the complexity of PD
pathogenesis, however, we agree with Drs Lang and Obeso that
current and future research should focus on the use of cellular
approaches to support essential circuitry and all affected cell
types in PD.2,5 These multifaceted roles for emerging cellular
therapies represent highly important and promising mechanisms
of neuroprotection for PD. Most likely, combining cellular
replacement with multidimensional support is essential for neu-
roprotection not only to dopaminergic neurons but to all other
cell types and neuronal pathways affected by PD.
Overall, the capacity of stem cell technologies to treat
neurodegenerative diseases is still a relatively new concept, and
much work remains to be done before these approaches pro-
gress into realistic and tangible clinical treatments and cures.
We acknowledge that there are remaining issues to address and
that it can take over a decade to translate promising treatments
to the clinic.1,3 With continued advances in stem cell technolo-
gies and continued comprehension of mechanisms responsible
for disease onset and progression, however, we can learn from
previous results and evolve new innovative approaches for treat-
ing neurodegenerative disorders to maximize the potential of
stem cell therapies and support the growing public hope.
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Nonequivalence of Equivalence Methods
Laura S. Boylan, MD,1,2 and Joshua J. Gagne, PharmD, ScD3
Krauss and colleagues reviewed the bioequivalence of
generic antiepileptic drugs (AEDs) by analyzing US Food and
Drug Administration data for generic approval, using these data
to indirectly compare generic–generic bioequivalence.1 The
authors sound a cautionary note regarding generic to generic
switching, but do not acknowledge an important limitation to
indirect comparisons.
When indirectly comparing 2 independent estimates, the
variance of the resulting estimate will always be larger than the
variance of each original estimate. That is, the variance of
the ratio indirectly comparing 2 generic AEDs (ie, [SE12 þ
SE22]1/2 from Krauss et al1) will always be greater than the var-
iance of each of the individual generic–brand ratios (i.e. SE12
or SE22), because the former must account for uncertainty in
both ratios being compared. Readers might misconstrue this
larger variance as a reflection of nonequivalence between the
2 generics rather than as nonequivalence between direct and
indirect comparison methods.
Consider the following scenario. Generic drug A is bioe-
quivalent to a brand name product with an area under the
curve (AUC)0–t ratio of 1.0 (90% confidence interval [CI],
0.81–1.23), and generic drug B is bioequivalent to the same
brand name product with an AUC0–t ratio of 1.0 (90% CI,
0.81–1.23). The resulting ratio of these ratios is also 1.0, but
with a 90% CI of 0.74 to 1.35. Therefore, large maximum lim-
its of 90% CIs, even up to 35% as shown in the authors’ Fig-
ures 4 and 5, are not unexpected even under perfect bioequiva-
lence or in indirectly comparing batch to batch variability of
brand medications.2 Thus, clinicians concerned about generic
AED bioequivalence should be reassured by Krauss et al’s
results.
Most importantly, the clinical relevance of small varia-
tions in bioavailability among generic drugs in epilepsy is
unsubstantiated. A recent meta-analysis of randomized studies
did not find a difference in seizure outcomes among patients
treated with generic AEDs as compared to those treated with
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